HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Preoperative infusional chemoradiation therapy for stage T3 rectal cancer.

AbstractPURPOSE:
To evaluate preoperative infusional chemoradiation for patients with operable rectal cancer.
METHODS AND MATERIALS:
Preoperative chemoradiation therapy using infusional 5-fluorouracil (5-FU), (300 mg/m2/day) together with daily irradiation (45 Gy/25 fractions/5 weeks) was administered to 77 patients with clinically Stage T3 rectal cancer. Endoscopic ultrasound confirmed the digital rectal exam in 63 patients. Surgery was performed approximately 6 weeks after the completion of chemoradiation therapy and included 25 abdominoperineal resections and 52 anal-sphincter-preserving procedures.
RESULTS:
Posttreatment tumor stages were T1-2, N0 in 35%, T3 N0 in 25%, and T1-3, N1 in 11%; 29% had no evidence of tumor. Local tumor control after chemoradiation was seen in 96% (74 out of 77); 2 patients had recurrent disease at the anastomosis site and were treated successfully with abdominoperineal resection. Overall, pelvic control was obtained in 99% (76 out of 77). The survival after chemoradiation was higher in patients without node involvement than in those having node involvement (p = n.s.). More patients with pathologic complete responses or only microscopic foci survived than did patients who had gross residual tumor (p = 0.07). The actuarial survival rate was 83% at 3 years; the median follow-up was 27 months, with a range of 3 to 68 months. Acute, perioperative, and late complications were not more numerous or more severe with chemoradiation therapy than with traditional radiation therapy (XRT) alone.
CONCLUSIONS:
Excellent treatment response allowed two-thirds of the patients to have an anal-sphincter-sparing procedure. Gross residual disease in the resected specimen indicates a poor prognosis, and therapies specifically targeting these patients may improve survival further.
AuthorsT A Rich, J M Skibber, J A Ajani, D J Buchholz, K R Cleary, R A Dubrow, B Levin, P M Lynch, S H Meterissian, L D Roubein
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 32 Issue 4 Pg. 1025-9 (Jul 15 1995) ISSN: 0360-3016 [Print] United States
PMID7607922 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Fluorouracil
Topics
  • Adenocarcinoma (drug therapy, mortality, pathology, radiotherapy, surgery)
  • Adult
  • Aged
  • Aged, 80 and over
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Female
  • Fluorouracil (administration & dosage, adverse effects)
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Preoperative Care
  • Rectal Neoplasms (drug therapy, mortality, pathology, radiotherapy, surgery)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: